{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:30:27Z","timestamp":1787502627196,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 81873426"],"award-info":[{"award-number":["Grant No. 81873426"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed\/refractory (R\/R) hematological malignancies, especially in R\/R B-cell acute lymphocytic leukemia (B-ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM). To prevent disease progression and reduce tumor burden during CAR-T cell manufacturing, bridging therapies prior to CAR-T cell infusion are crucial. At present, it has been demonstrated that targeted therapy, radiotherapy and autologous stem cell transplantation (ASCT) could serve as effective bridging strategies. However, whether cryoablation could serve as a novel bridging strategy is unknown. In this paper, we report 2 cases of R\/R B cell malignancies with bulky disease that were successfully treated with a combination of cryoablation and CAR-T cell therapy. Patient 1 was a 65-year-old female who was diagnosed with R\/R MM with extramedullary disease (EMD). She was enrolled in the anti-BCMA CAR-T cell clinical trial. Patient 2 was a 70-year-old man who presented with a subcutaneous mass in the right anterior thigh and was diagnosed with primary cutaneous diffuse large B cell lymphoma, leg type (PCLBCL-LT) 1 year ago. He failed multiline chemotherapies as well as radiotherapy. Thus, he requested anti-CD19 CAR-T cell therapy. Unfortunately, they all experienced local progression during CAR-T cell manufacturing. To rapidly achieve local tumor control and reduce tumor burden, they both received cryoablation as a bridging therapy. Patient 1 achieved a very good partial response (VGPR) 1 month after CAR-T cell infusion, and patient 2 achieved a partial response (PR) 1 month after CAR-T cell infusion. In addition, adverse effects were tolerable and manageable. Our study demonstrated the favorable safety and efficacy of combination therapy with cryoablation and CAR-T cell therapy for the first time, and it also indicates that cryoablation could serve as a novel therapeutic strategy for local tumor control in B cell malignancies.<\/jats:p>","DOI":"10.3389\/fonc.2023.1008828","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T02:10:22Z","timestamp":1674785422000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case report: Cryoablation as a novel bridging strategy prior to CAR-T cell therapy for B cell malignancies with bulky disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaomin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaolin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongcheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large b-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a b-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological malignancies: Current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN guidelines\u00ae insights: B-cell lymphomas, version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/d41573-022-00048-8","article-title":"FDA Approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discovery"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: Patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01196-3","article-title":"Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia","volume":"35","author":"Perica","year":"2021","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0551","article-title":"BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy","volume":"7","author":"Smith","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging radiation therapy prior to commercial chimeric antigen receptor T-cell therapy for relapsed\/refractory aggressive b-cell lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large b-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01632-7","article-title":"Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large b cell lymphoma","volume":"57","author":"Galli","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrc3672","article-title":"Thermal ablation of tumours: biological mechanisms and advances in therapy","volume":"14","author":"Chu","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-11157-w","article-title":"Tumor-infiltrating lymphocytes (TILs) as a biomarker of abscopal effect of cryoablation in breast cancer: A pilot study","volume":"29","author":"Khan","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1326441","article-title":"Characterization of the cryoablation-induced immune response in kidney cancer patients","volume":"6","author":"Kato","year":"2017","journal-title":"Oncoimmunology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02566-z","article-title":"Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: An ambispective, proof-of-concept cohort study","volume":"69","author":"Shen","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cryobiol.2018.04.013","article-title":"Percutaneous ablative cryoimmunotherapy for micrometastaic abscopal effect: No complications","volume":"82","author":"Soule","year":"2018","journal-title":"Cryobiology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2422","article-title":"Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity","volume":"11","author":"Machlenkin","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-017-8927x","article-title":"Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer","volume":"65","author":"Lin","year":"2017","journal-title":"Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1782","article-title":"Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy","volume":"72","author":"Waitz","year":"2012","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.7452","article-title":"Improvement of survival in patients with primary cutaneous diffuse large b-cell lymphoma, leg type, in France","volume":"150","author":"Grange","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large b-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2958","article-title":"Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease","volume":"40","author":"Li","year":"2022","journal-title":"Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.720571","article-title":"Efficacy of humanized anti-BCMA CAR T cell therapy in Relapsed\/Refractory multiple myeloma patients with and without extramedullary disease","volume":"12","author":"Deng","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2014.08.011","article-title":"Cryoablation of sternal metastases for pain palliation and local tumor control","volume":"25","author":"Hegg","year":"2014","journal-title":"J Vasc Interv Radiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-016-1339-3","article-title":"Salvage cryotherapy with third-generation technology for locally recurrent prostate cancer after radiation therapy","volume":"48","author":"Lian","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2009.10.053","article-title":"Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model","volume":"147","author":"Jansen","year":"2010","journal-title":"Surgery"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0013","article-title":"Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy","volume":"4","author":"Page","year":"2016","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1008828\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T02:10:26Z","timestamp":1674785426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1008828\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":31,"alternative-id":["10.3389\/fonc.2023.1008828"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1008828","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"article-number":"1008828"}}